The company is responding to an increased demand for injectable pharmaceuticals, SCA Pharma spokesperson Matthew Cronk told In-PharmaTechnologst.com.
Hospitals are contracting numerous injectables suppliers, so as to safeguard their supply, which has also increased demand, he said.
Connecticut State’s Department of Economic and Community Development (DECD) is supporting the construction with a $8.5m (€7.81m) loan for leasehold improvements and the purchase of machinery and equipment.
SCA Pharma expects to create approximately 361 new jobs over the next four years.
“This is an important sector of our economy, and we are thrilled that this company is adding hundreds of good, high-quality jobs in our state,” said State of Connecticut governor Dannel Malloy.
Connecticut lt. governor Nancy Wyman also expressed support for the industry, “These investments position us to attract new business and development, grow jobs, and further establish Connecticut as a global competitor in bioscience and healthcare.”
SCA Pharma expects to open the facility in August.
The company currently manufactures injectable pharmaceuticals in ready-to-administer dosages for use at hospitals and healthcare facilities at its facility in Arkansas, US.
Injectable pharmaceuticals shortage
The announcement comes four years after the closure of one of the world’s largest sterile injectables manufacturer, Ben Venue Laboratories.
Years of quality and GMP issues at Ben Venue’s Ohio, US-based site caused major drug shortages at the beginning of the decade.